Clinical Trial Update: A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the safety and tolerability of different doses of PF-06444753 and PF-06444752 in adults with allergic rhinitis, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• PF-06444752
• PF-06444753

Snippet

Sponsor: Pfizer | Conditions: Allergic Rhinitis | Phase 1 | Status: COMPLETED | Results posted: 2016-07-11